BiomX Accelerates Defense Technology Buildout with DFSL Acquisition

BiomX Inc. (PHGE) announced it has accelerated its option to acquire a controlling interest in DFSL, an Israeli defense engineering company specializing in LADAR-based detection systems for perimeter security and counter-UAS applications. The acquisition complements BiomX's recent Zorronet AI command-and-control platform acquisition, creating an integrated detection and response system. The transaction requires Israeli regulatory approval and NYSE American shareholder approval.

04/13/2026, 9:20 AM • Benzinga

BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications

BiomX Inc. (NYSE: PHGE) has completed the acquisition of Zorronet from Water.io, an AI-powered command-and-control software platform that integrates video analytics, drones, sensors, and IoT devices for defense and security applications. The acquisition marks BiomX's entry into the defense sector and complements its option to acquire DFSL, a LADAR solutions company. The global command and control systems market is projected to reach $44 billion by 2030.

04/10/2026, 8:30 AM • Benzinga

BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System

BiomX Inc. (PHGE) announced it has entered into an option agreement to acquire control of DFSL, an Israeli developer of LADAR-based detection systems for security, defense, and critical infrastructure. DFSL's proprietary AI-integrated laser radar technology achieves approximately 99% accuracy in detecting UAVs and ground-based threats while significantly reducing false alarms. The acquisition marks BiomX's strategic pivot into the defense and security sectors, targeting the counter-drone market expected to reach $14 billion by 2030 and the perimeter security market projected to exceed $130 billion by 2030.

03/31/2026, 10:48 AM • Benzinga

BiomX Announces $3.0 Million Private Placement

BiomX Inc. announced a private placement financing of approximately $3.0 million gross proceeds through the issuance of Series Y Convertible Preferred Stock and warrants. The company plans to use net proceeds to assess opportunities for its bacteriophage programs, including BX011 for diabetic foot infections, and for general corporate purposes while evaluating strategic alternatives.

12/29/2025, 8:00 AM • GlobeNewswire

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

BiomX initiated a Phase 2b clinical trial for BX004, a phage therapy targeting Pseudomonas aeruginosa infections in cystic fibrosis patients. The trial involves 60 patients and aims to evaluate bacterial reduction, lung function improvements, and quality of life metrics, with topline results expected in Q1 2026.

07/14/2025, 9:00 AM • GlobeNewswire